Conference Paper: Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene

File Download

re01.htm

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1111/j.1742-7843.2011.00722.x

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:

Title	Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
Authors	Cheung, BMY Ong, KL Tso, AWK Leung, RYH Cherny, SS Sham, PC Lam, TH Lam, KSL
Keywords	Pharmacy and pharmacology environmental studies Toxicology and environmental safety
Issue Date	2011
Publisher	Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
Citation	The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146 [How to Cite?] DOI: http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
Abstract	INTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.
Description	This journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics Posters
ISSN	1742-7835 2011 Impact Factor: 2.179 2011 SCImago Journal Rankings: 0.129
DOI	http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x

DC Field	Value
dc.contributor.author	Cheung, BMY
dc.contributor.author	Ong, KL
dc.contributor.author	Tso, AWK
dc.contributor.author	Leung, RYH
dc.contributor.author	Cherny, SS
dc.contributor.author	Sham, PC
dc.contributor.author	Lam, TH
dc.contributor.author	Lam, KSL
dc.date.accessioned	2011-08-26T14:33:02Z
dc.date.available	2011-08-26T14:33:02Z
dc.date.issued	2011
dc.description.abstract	INTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.
dc.description.nature	link_to_OA_fulltext
dc.description	This journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
dc.description	Posters
dc.description.other	The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146
dc.identifier.citation	The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146 [How to Cite?] DOI: http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
dc.identifier.doi	http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
dc.identifier.epage	103
dc.identifier.hkuros	189576
dc.identifier.issn	1742-7835 2011 Impact Factor: 2.179 2011 SCImago Journal Rankings: 0.129
dc.identifier.issue	suppl. s1
dc.identifier.spage	102
dc.identifier.uri	http://hdl.handle.net/10722/137759
dc.identifier.volume	109
dc.language	eng
dc.publisher	Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
dc.publisher.place	United Kingdom
dc.relation.ispartof	Basic & Clinical Pharmacology & Toxicology
dc.rights	The definitive version is available at www.blackwell-synergy.com
dc.subject	Pharmacy and pharmacology environmental studies
dc.subject	Toxicology and environmental safety
dc.title	Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Cheung, BMY</contributor.author><contributor.author>Ong, KL</contributor.author><contributor.author>Tso, AWK</contributor.author><contributor.author>Leung, RYH</contributor.author><contributor.author>Cherny, SS</contributor.author><contributor.author>Sham, PC</contributor.author><contributor.author>Lam, TH</contributor.author><contributor.author>Lam, KSL</contributor.author><date.accessioned>2011-08-26T14:33:02Z</date.accessioned><date.available>2011-08-26T14:33:02Z</date.available><date.issued>2011</date.issued><identifier.citation>The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic &amp; Clinical Pharmacology &amp; Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146</identifier.citation><identifier.issn>1742-7835</identifier.issn><identifier.uri>http://hdl.handle.net/10722/137759</identifier.uri><description>This journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics</description><description>Posters</description><description.abstract>INTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6&#8211;20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5&#8211;17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.</description.abstract><language>eng</language><publisher>Blackwell Publishing Ltd. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/PTO</publisher><relation.ispartof>Basic &amp; Clinical Pharmacology &amp; Toxicology</relation.ispartof><rights>The definitive version is available at www.blackwell-synergy.com</rights><subject>Pharmacy and pharmacology environmental studies</subject><subject>Toxicology and environmental safety</subject><title>Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene</title><type>Conference_Paper</type><description.nature>link_to_OA_fulltext</description.nature><identifier.doi>10.1111/j.1742-7843.2011.00722.x</identifier.doi><identifier.hkuros>189576</identifier.hkuros><identifier.volume>109</identifier.volume><identifier.issue>suppl. s1</identifier.issue><identifier.spage>102</identifier.spage><identifier.epage>103</identifier.epage><publisher.place>United Kingdom</publisher.place><description.other>The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic &amp; Clinical Pharmacology &amp; Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/137759/1/re01.htm</bitstream.url></item>